The financials
HUTCHMED (China) Limited by the numbers
HUTCHMED (China) Limited (HCM) reported revenue of $271M in H2 2025 (quarter ended December 31, 2025), down 11% from the same quarter a year earlier. That came with a gross margin of 38% and net income of $2.0M (0.7% of revenue). For the full year FY2025, revenue was $549M (−13% year on year) and net income $457M.
| Income statement | H2 2025 | H2 2023 | Change |
|---|---|---|---|
| Revenue | $271M | $305M | −11% |
| Gross profit | $102M | n/a | n/a |
| Operating income | −$36M | −$93M | n/a |
| Net income | $2.0M | −$68M | to a profit |
| Diluted EPS | $0.00 | −$0.07 | to a profit |
Drug Manufacturers - Specialty & Generic
The closest names by size in the same industry